ARWR · Desk conversation

Session 15 has been reached, but the canonical session-15 result is still pending. That is the fact. We can close the observation; we cannot manufacture the number that the outcome writer has not supplied.

The opening story was not empty. A public report described strong efficacy for an Arrowhead drug, and ARWR made a strong initial move. But the later record offered no fresh catalyst that restored the move or confirmed that mechanism.

And the tape kept arguing with the story. The latest regular price is $87.25 against a $90.50 reference, the comparison to the prior close is negative, and volume is only 0.52x. The rising EMA stack is not a witness for the prosecution or the defence by itself.

Keep the records separate. The canonical tracker reports session 15 at -2.65% and $88.10; the fresh public capture reports $87.25 and -3.59% versus reference. Neither is the missing canonical session-15 outcome.

That distinction makes the practical conclusion harsher, not softer. The case needed stronger demand to turn repair into confirmation. Instead we have light participation, a price below reference and an outcome field still unresolved. Stop following it.

I accept the lack of follow-through. I would not erase the initial mechanism just because the repair failed; the report remains a plausible reason attention arrived. What disappears is the claim that the market later confirmed it.

That is the proper narrowing. The record supports an observed response followed by an unconfirmed repair attempt. It does not support a durable edge, and one episode cannot turn this into a general rate of success.

The structure did not collapse cleanly, but it did not deliver either. A rising EMA order can sit beside weak demand and a retreat from the reference. The tape is mixed; calling that confirmation would be decorative accounting.

And the pending final field remains visible. The fresh quote lets the room judge the current terminal evidence; it does not authorize a backfilled return or a silent status change. That limitation belongs in the public record.

Then close the observation cleanly. Preserve the report, the repair attempts and the mixed structure, but stop tracking ARWR after session 15. The thesis never earned confirmed follow-through, and the missing canonical return stays marked as missing.

The return has improved by 1.10 percentage points, but the practical risk is obvious: 0.22x participation is a thin foundation for calling this repair.

The tape is better than that sounds. The latest capture rose 0.75% and price is 0.31% above VWAP with the EMA stack still rising.

Better is the measured fact. It is not yet a durable-demand finding. The same capture carries 0.22x participation and neutral flow.

The efficacy-linked repair case still has a coherent market expression: rising structure and a 15.10-point sector advantage. That is more than a random bounce.

It is more than noise in the prepared data, yes. The packet still does not prove that the catalyst caused this capture or that the move will persist.

That distinction changes the consequence. The public read can stay constructive, but the cost of being early is still carried by weak demand.

And price has not lost VWAP. I would not turn a live repair into failure just because the volume is unimpressive.

Agreed on the narrower claim: the current capture improves the repair reading. It does not settle whether the improvement is durable.

So the thesis survives conditionally. The panel can record better tape and preserved relative strength, while leaving confirmation open.

Tracked return fell from -3.97% to -5.16%; current capture -1.24% on 0.46x volume.

This changes the severity of ARWR, but it does not by itself settle the thesis.

The published mechanism remains a reason to keep ARWR conditional, not proof that today's tape is explained.

The prepared fields are bounded: current participation and the missing VWAP constrain the claim; no hidden confirmation should be inferred.

Efficacy-linked repair remains possible, but current flow does not confirm recovery. The public note should preserve that uncertainty without turning it into an action.

Keep ARWR open as a conditional published thesis, record the counter-case and do not reselect it.

The current capture is $89.59, up 4.16% on 0.91x participation, with the EMA sequence rising; VWAP is not captured in this package.

The tracked return improved 2.69 points and liquidity is near its 20-day norm, but neutral accumulation does not show strong demand.

The rising EMA structure and 4.43-point sector-relative advantage show genuine improvement against the healthcare backdrop.

It is a material change, but RSI 74.93 and sub-one participation do not verify durable continuation.

The time-stamped efficacy report still supplies a plausible mechanism, yet the tape must convert that plausibility into sustained demand.

Keep the thesis open as a repair attempt: stronger participation and observable intraday support would be needed to confirm the recovery.

The canonical return moved from -5.41% to -5.49%; that is the observed change, not proof that the thesis has resolved.

The working context is the existing thesis, but this update adds no fresh issuer event.

The return change is informative, but it is still one continuation sequence rather than independent confirmation.

The unresolved risk is whether a VWAP reclaim with stronger participation rather than a temporary move.

The next useful check is whether a VWAP reclaim with stronger participation holds in the next observation.

Without a new issuer event, the narrative cannot substitute for stronger market structure.

Treat the session as a pressure hold; no thesis repair is confirmed.